// App-Quantinova.ai

4300 : Design of the Hallmarq Trial, a Phase 3 Study of Vincristine Sulfate Liposome Injection (VSLI, Marqibo) in Adults with Newly Diagnosed, Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Steven R. Deitcher

Principal Investigators

  • Jeffrey A Silverman

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • Talon Therapeutics,

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

  • Ph chromosome

Drug/Treatment

  • Vincristine

  • Asparaginase

Outcome

  • N/A

Study Design

  • randomized

  • double blind/blinded

  • superiority

  • pharmacokinetics

Phase

  • III

Study Id's

  • NCT01439347

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved